38.06

4.10% 1.50

Pre-market: 38.51 0.45 +1.18%

Xenon Pharmaceuticals Inc (XENE)

Overview News Price History Option Chain Financials Discussions Forecast

Xenon Pharmaceuticals Inc stock is traded at $38.06, with a volume of 3.11M. It is up +4.10% in the last 24 hours and down -37.15% over the past month. Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

Previous Close:

$36.56

Open:

$36.5

24h Volume:

3.11M

Relative Volume:

2.16

Market Cap:

$3.69B

Revenue:

$7.50M

Net Income/Loss:

$-383.17M

P/E Ratio:

-8.0896

EPS:

-4.7048

Net Cash Flow:

$-307.84M

1W Performance:

-33.64%

1M Performance:

-37.15%

6M Performance:

-28.70%

1Y Performance:

+4.02%

1-Day Range:

$36.07

$38.34

1-Week Range:

$36.07

$44.85

52-Week Range:

$35.97

$72.66

Xenon Pharmaceuticals Inc Stock (XENE) Company Profile

Name

Xenon Pharmaceuticals Inc

Sector

Healthcare (1068)

Industry

Biotechnology (595)

Phone

(604) 484-3300

Address

200 - 3650 GILMORE WAY, BURNABY

Employee

370

Twitter

Next Earnings Date

2026-11-02

Latest SEC Filings

XENE's Discussions on Twitter

Compare XENE vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XENE Xenon Pharmaceuticals Inc	38.06	3.69B	7.50M	-383.17M	-307.84M	-4.7048
VRTX Vertex Pharmaceuticals Inc	522.38	132.40B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	796.02	81.95B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	194.82	77.78B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	962.22	60.20B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	199.86	42.84B	742.00K	-1.37B	-1.07B	-7.0731

Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-26	Initiated	Wolfe Research	Outperform
Sep-03-25	Resumed	Wells Fargo	Overweight
May-07-25	Initiated	Chardan Capital Markets	Buy
Feb-11-25	Initiated	Deutsche Bank	Buy
Oct-10-24	Resumed	Raymond James	Outperform
Oct-01-24	Initiated	H.C. Wainwright	Buy
Jan-04-24	Initiated	Citigroup	Buy
Dec-08-23	Initiated	Robert W. Baird	Outperform
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Apr-25-23	Initiated	Cantor Fitzgerald	Overweight
Dec-14-22	Initiated	Goldman	Buy
Dec-12-22	Initiated	Cowen	Outperform
Nov-28-22	Initiated	Wells Fargo	Overweight
Oct-19-22	Initiated	Raymond James	Outperform
Aug-29-22	Initiated	BofA Securities	Buy
Jul-21-22	Initiated	JP Morgan	Overweight
Oct-28-21	Initiated	RBC Capital Mkts	Outperform
Oct-02-20	Initiated	SVB Leerink	Outperform
Jul-21-20	Initiated	Needham	Buy
Jun-01-20	Resumed	Jefferies	Buy
Mar-25-20	Initiated	Wedbush	Outperform
Jan-08-20	Initiated	William Blair	Outperform
Sep-20-19	Initiated	Guggenheim	Buy
Aug-08-18	Reiterated	Stifel	Buy
Mar-13-17	Initiated	Jefferies	Buy
Oct-21-16	Initiated	Stifel	Buy
Sep-26-16	Initiated	Guggenheim	Buy
Apr-14-16	Reiterated	Jefferies	Buy
Oct-30-15	Resumed	Jefferies	Buy
Dec-02-14	Initiated	Canaccord Genuity	Buy

View All

Xenon Pharmaceuticals Inc Stock (XENE) Latest News

Sep 24, 2026

(XENE) Volatility Zones as Tactical Triggers - Stock Traders Daily

Sep 24, 2026